01.19.26 -- Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos

Discover how one family's race against time led to the creation of a groundbreaking gene therapy for their daughter, just 14 months after her ultra-rare disease diagnosis.

Real-time release and digital quality management, powered by PAT, are driving efficiency and compliance, reshaping how manufacturers achieve speed, consistency, and competitive advantage.

Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation — helping companies move therapies forward with greater confidence.

Digital transformation begins with a clear framework. Explore a Maturity Model 3.0 that helps biomanufacturers assess and advance digital capabilities, enabling smarter decisions and long-term innovation.

The pre‑filled syringe market is rapidly growing thanks to safety and cost benefits. But “pre‑filled” isn’t always easy. Biologic drugs driving this growth pose filling challenges due to high viscosity.

Enrollment isn’t a marketing issue; it’s an operational imperative. PXO gives clinical teams predictable conversions, better data quality, and a patient‑centered system to close the Enrollment Abyss.

Continuous biomanufacturing is reshaping how active pharmaceutical ingredients are produced. Learn how modular, automated virus inactivation solutions are helping manufacturers improve efficiency.